Swiss National Bank Makes New Investment in Annexon, Inc. $ANNX

by · The Markets Daily

Swiss National Bank bought a new stake in shares of Annexon, Inc. (NASDAQ:ANNX – Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund bought 236,000 shares of the company’s stock, valued at approximately $1,307,000.

A number of other large investors also recently made changes to their positions in ANNX. AQR Capital Management LLC boosted its position in shares of Annexon by 122.6% in the 1st quarter. AQR Capital Management LLC now owns 73,790 shares of the company’s stock worth $142,000 after purchasing an additional 40,637 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Annexon by 8.2% during the first quarter. Jane Street Group LLC now owns 99,924 shares of the company’s stock worth $193,000 after purchasing an additional 7,553 shares during the period. Acadian Asset Management LLC increased its holdings in Annexon by 31.1% in the first quarter. Acadian Asset Management LLC now owns 203,990 shares of the company’s stock valued at $393,000 after purchasing an additional 48,345 shares during the last quarter. Geode Capital Management LLC increased its holdings in Annexon by 1.8% in the second quarter. Geode Capital Management LLC now owns 2,284,773 shares of the company’s stock valued at $5,484,000 after purchasing an additional 39,763 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Annexon by 6.6% in the second quarter. American Century Companies Inc. now owns 211,195 shares of the company’s stock valued at $507,000 after purchasing an additional 13,001 shares during the last quarter.

Analyst Upgrades and Downgrades

ANNX has been the topic of a number of recent analyst reports. Needham & Company LLC raised their target price on Annexon from $11.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Annexon in a research note on Friday, July 17th. The Goldman Sachs Group initiated coverage on shares of Annexon in a research report on Tuesday, May 12th. They issued a “neutral” rating and a $7.00 price target on the stock. Citizens Jmp began coverage on shares of Annexon in a research note on Tuesday, July 21st. They set a “market underperform” rating and a $3.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Annexon from a “hold” rating to a “sell” rating in a research note on Sunday, July 12th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $15.33.

Read Our Latest Analysis on ANNX

Insider Transactions at Annexon

In other Annexon news, Director William H. Carson acquired 8,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $5.78 per share, for a total transaction of $46,240.00. Following the acquisition, the director directly owned 78,405 shares of the company’s stock, valued at approximately $453,180.90. This trade represents a 11.36% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Muneer A. Satter acquired 613,497 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was acquired at an average price of $5.41 per share, with a total value of $3,319,018.77. Following the completion of the transaction, the director directly owned 10,342,134 shares in the company, valued at $55,950,944.94. This trade represents a 6.31% increase in their position. The disclosure for this purchase is available in the SEC filing. Company insiders own 10.31% of the company’s stock.

Annexon Stock Down 3.4%

ANNX opened at $5.09 on Friday. The stock has a market cap of $833.95 million, a P/E ratio of -4.17 and a beta of 1.16. Annexon, Inc. has a 12 month low of $2.03 and a 12 month high of $7.18. The company has a fifty day simple moving average of $5.36 and a 200 day simple moving average of $5.58.

Annexon (NASDAQ:ANNX – Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.07. On average, equities research analysts expect that Annexon, Inc. will post -0.92 earnings per share for the current fiscal year.

Annexon Profile

(Free Report)

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.

See Also

Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNX – Free Report).